Live
- Former MLA was ready to marry ‘fraudster’ Shweta Gowda
- Horoscope Today, December 26, 2024: Check Here for Astrological Daily Predictions
- KTR Condemns Arrest of Errolla Srinivas, Calls it an Unjust Act
- Meeting of Film Industry Leaders with CM Revanth Reddy
- Heavy Rush of Devotees at Tirumala Temple
- Belagavi meet is Jai Bapu-Jai Bhim-Jai Samvidhan convention
- Four Karnataka soldiers martyred in J&K Army vehicle accident
- Madhya Pradesh to translocate 14 tigers to Gujarat, Chhattisgarh, Odisha
- Shiva Rajkumar gets cancerous bladder removed in US
- Modi: Ambedkar's vision neglected by Congress
Zydus gets final approval from US FDA for Type 2 diabetes pills
Indian pharma company Zydus Lifesciences on Friday said that it has received final approval from the US Food and Drug Administration (USFDA) to market tablets for Type 2 diabetes.
Ahmedabad: Indian pharma company Zydus Lifesciences on Friday said that it has received final approval from the US Food and Drug Administration (USFDA) to market tablets for Type 2 diabetes.
The drugmaker said it got “approval for its New Drug Application (NDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets”.
With this, Zydus has all three NDAs of Sitagliptin (base) and combination franchise approved, it added.
"Notably, all the three NDAs achieved first-cycle approval (FCA)," the company stated.
Further, it added that the product will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.
According to IQVIA (MAT May 2024), the US market for DPP-IV inhibitors and its combinations is $9.5 bn.
